Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Nail irregularities associated with Sézary syndrome.

Park K, Reed J, Talpur R, Duvic M.

Cutis. 2019 Apr;103(4):E11-E16.

PMID:
31116823
2.

Identification of geographic clustering and regions spared by cutaneous T-cell lymphoma in Texas using 2 distinct cancer registries.

Litvinov IV, Tetzlaff MT, Rahme E, Habel Y, Risser DR, Gangar P, Jennings MA, Pehr K, Prieto VG, Sasseville D, Duvic M.

Cancer. 2015 Jun 15;121(12):1993-2003. doi: 10.1002/cncr.29301. Epub 2015 Feb 27.

3.

Nail Alterations in Cutaneous T-Cell Lymphoma: A Case Series and Review of Nail Manifestations.

Bishop BE, Wulkan A, Kerdel F, El-Shabrawi-Caelen L, Tosti A.

Skin Appendage Disord. 2015 Sep;1(2):82-6. doi: 10.1159/000433474. Epub 2015 Jul 3. Review.

4.

Extracorporeal photophoresis: an evidence-based analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1.

5.

Demographic patterns of cutaneous T-cell lymphoma incidence in Texas based on two different cancer registries.

Litvinov IV, Tetzlaff MT, Rahme E, Jennings MA, Risser DR, Gangar P, Netchiporouk E, Moreau L, Prieto VG, Sasseville D, Duvic M.

Cancer Med. 2015 Sep;4(9):1440-7. doi: 10.1002/cam4.472. Epub 2015 Jul 1.

6.

Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.

Ghazawi FM, Netchiporouk E, Rahme E, Tsang M, Moreau L, Glassman S, Provost N, Gilbert M, Jean SE, Pehr K, Sasseville D, Litvinov IV.

Cancer. 2017 Sep 15;123(18):3550-3567. doi: 10.1002/cncr.30758. Epub 2017 May 10.

7.

An association between newly diagnosed cutaneous T cell lymphoma and prior impetigo: a nested case-control study.

Boursi B, Haynes K, Mamtani R, Yang YX.

Arch Dermatol Res. 2016 Nov;308(9):661-664. Epub 2016 Sep 9.

PMID:
27613059
8.

Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS).

Shalabi D, Bistline A, Alpdogan O, Kartan S, Mishra A, Porcu P, Nikbakht N.

Chin Clin Oncol. 2019 Feb;8(1):11. doi: 10.21037/cco.2019.01.01. Epub 2019 Jan 9. Review.

9.

Sézary syndrome without erythroderma: A review of 16 cases at Mayo Clinic.

Thompson AK, Killian JM, Weaver AL, Pittelkow MR, Davis MD.

J Am Acad Dermatol. 2017 Apr;76(4):683-688. doi: 10.1016/j.jaad.2016.10.029. Epub 2016 Dec 21.

PMID:
28012574
10.

Sézary syndrome and related variants of classic cutaneous T-cell lymphoma. A descriptive and prognostic clinicopathologic study of 29 cases.

Marti RM, Pujol RM, Servitje O, Palou J, Romagosa V, Bordes R, González-Castro J, Miralles J, Gallardo F, Curcó N, Gómez X, Domingo A, Estrach T.

Leuk Lymphoma. 2003 Jan;44(1):59-69.

PMID:
12691143
11.

CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214.

Benoit BM, Jariwala N, O'Connor G, Oetjen LK, Whelan TM, Werth A, Troxel AB, Sicard H, Zhu L, Miller C, Takeshita J, McVicar DW, Kim BS, Rook AH, Wysocka M.

Arch Dermatol Res. 2017 Jan;309(1):11-19. doi: 10.1007/s00403-016-1698-8. Epub 2016 Oct 20.

12.

Sézary Syndrome, recent biomarkers and new drugs.

Cristofoletti C, Narducci MG, Russo G.

Chin Clin Oncol. 2019 Feb;8(1):2. doi: 10.21037/cco.2018.11.02. Epub 2018 Nov 28. Review.

13.

Ectopic expression of embryonic stem cell and other developmental genes in cutaneous T-cell lymphoma.

Litvinov IV, Netchiporouk E, Cordeiro B, Zargham H, Pehr K, Gilbert M, Zhou Y, Moreau L, Woetmann A, Ødum N, Kupper TS, Sasseville D.

Oncoimmunology. 2014 Dec 21;3(11):e970025. eCollection 2014 Nov.

14.

Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.

Vidulich KA, Talpur R, Bassett RL, Duvic M.

Int J Dermatol. 2009 Mar;48(3):243-52. doi: 10.1111/j.1365-4632.2009.03771.x.

PMID:
19261011
15.

BCL2 and JUNB abnormalities in primary cutaneous lymphomas.

Mao X, Orchard G, Lillington DM, Child FJ, Vonderheid EC, Nowell PC, Bagot M, Bensussan A, Russell-Jones R, Young BD, Whittaker SJ.

Br J Dermatol. 2004 Sep;151(3):546-56.

PMID:
15377339
16.

The utility of bexarotene in mycosis fungoides and Sézary syndrome.

Panchal MR, Scarisbrick JJ.

Onco Targets Ther. 2015 Feb 3;8:367-73. doi: 10.2147/OTT.S61308. eCollection 2015. Review.

17.

Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.

Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.

J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049. Review.

PMID:
24438969
18.

Analysis of CTCL cell lines reveals important differences between mycosis fungoides/Sézary syndrome vs. HTLV-1+ leukemic cell lines.

Netchiporouk E, Gantchev J, Tsang M, Thibault P, Watters AK, Hughes JM, Ghazawi FM, Woetmann A, Ødum N, Sasseville D, Litvinov IV.

Oncotarget. 2017 Oct 7;8(56):95981-95998. doi: 10.18632/oncotarget.21619. eCollection 2017 Nov 10.

19.

Paucity of FOXP3+ cells in skin and peripheral blood distinguishes Sézary syndrome from other cutaneous T-cell lymphomas.

Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N, Sykora J, Banham AH, Roncador G, Kuhn A, Goerdt S, Krammer PH, Suri-Payer E.

Leukemia. 2006 Jun;20(6):1123-9.

PMID:
16557241
20.

Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.

Martinez-Escala ME, Kuzel TM, Kaplan JB, Petrich A, Nardone B, Rosen ST, Guitart J.

JAMA Oncol. 2016 Jun 1;2(6):790-3. doi: 10.1001/jamaoncol.2016.0004.

PMID:
27054291

Supplemental Content

Support Center